Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Mesenchymal Stem Cell Protection and Chondrogenic Differentiation in Tracheal Fistula Therapy via Bioactive Platinum Nanozymes.

Shi L., Ji W., Zheng Q., Chen X., Shen H., Zhang G.

Animal Study on Cartilage Damage, Chronic Wound, Chronic Inflammation, Autoimmune Research, published in ACS Appl Mater Interfaces (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
ACS Appl Mater Interfaces (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40548842
DOI
10.1021/acsami.5c10441

Abstract (original English)

Stem cells are highly regarded in regenerative medicine for their ability to promote wound healing and tissue regeneration, exhibiting great potential for tracheal fistula (TF) repair. However, excessive reactive oxygen species (ROS) at damaged TF sites compromise stem cell viability, differentiation, and functional capacity. This challenge is particularly pronounced due to the limited intrinsic healing potential of the tracheal cartilage, which further complicates effective TF repair. Herein, we report the use of a sodium hyaluronate-platinum nanoparticle composite (SHA-PtNPs) to promote fistula healing while supporting the protection and chondrogenic differentiation of adipose-derived stem cells (ADSCs). In vitro experiments demonstrated that SHA-PtNPs significantly enhanced ADSCs' viability, migration, ROS scavenging, and anti-inflammatory activity. Under oxidative stress conditions, SHA-PtNPs promoted chondrogenic differentiation, as evidenced by upregulated expression of SRY-box transcription factor 9 (SOX-9), collagen type II alpha 1 chain (COL2A1), and aggrecan (ACAN). Strikingly, the combination of SHA-PtNPs and ADSCs achieved 100% healing by day 14 and facilitated cartilage regeneration, as confirmed by green fluorescent protein (GFP) labeling, verifying ADSC integration. Additionally, SHA-PtNPs-ADSCs reduced ROS levels and inhibited the NF-κB/IκBα/IL-1β signaling path

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
PlatinumMesenchymal Stem CellsChondrogenesisCell DifferentiationAnimalsReactive Oxygen SpeciesHumansHyaluronic AcidMetal NanoparticlesAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research